By Ms Haifa Lyster, Royal Brompton & Harefield NHS Foundation Trust
Aim
Build a simulated Physiologic Based Pharmacokinetic (PBPK) model for antifungal agents in a critically ill patient with ECMO; the role of ECMO as an independent variable in a critically ill patient with altered PK can be quantified.
Summary of potential benefits to patients and the NHS
The application of PK principles in both selecting the appropriate anti-infective and its dosage regimen is important in optimizing patient outcome. Changes in antibiotic PK can lead to either therapeutic failure or toxicity in the patient; however, the potential emergence of resistant bacteria or fungi has wider implications to the NHS.
This project was awarded funding in 2016 and ran from October 2016 to September 2017.
The final report is available here.
